FDA Approves Extended Shelf Life for Humacyte's Symvess Tissue

The U.S. Food and Drug Administration (FDA) has authorized Humacyte to extend the expiration of its Symvess bioengineered human tissue from 18 to 36 months. This decision, supported by additional stability data, aims to improve the commercial availability and inventory flexibility of Symvess for hospitals, facilitating urgent vascular repairs. This could enhance access to a critical medical product.